When telephone lines go down, or Internet connections are lost, our communities temporarily come to a halt. What if something similar were found to be happening in Parkinson's? This is the focus of Dr. Schmitz and her team at the PDF Research Center at Columbia University Medical Center.
PDF Grant Programs
Are you interested in furthering Parkinson's science? View PDF's open grant programs.
Ceftriaxone blocks the polymerisation of ?-synuclein and exerts neuroprotective effects in vitro.
PDF's targeted PubMed search provides you with access to journal articles from the last 90 days that may be pertinent to Parkinson's disease research.
Not what you're looking for? Do you need informational publications about Parkinson's targeted for people living with Parkinson's, caregivers and family members? Please browse PDF's educational materials and programs - which are all available electronically or in print. Order for yourself, a loved one or in bulk for your patients or support group.
ACS Chem Neurosci 2013 Oct;
Authors: Paolo Ruzza, Giuliano Siligardi, Rohanah Hussain, Anna Marchiani, Mehmet Islami, Luigi Bubacco, Giovanna Delogu, Davide Fabbri, Maria A Dettori, Mario Sechi, Nicolino Pala, Ylenia Spissu, Rossana Migheli, Pier A Serra, Gianpietro Sechi
The ?-lactam antibiotic ceftriaxone was suggested as a therapeutic agent in several neurodegenerative disorders, either for its ability to counteract glutamate-mediated toxicity, as in cerebral ischemia, or for its ability to enhance the degradation of misfolded proteins, as in Alexander's disease. Recently, the efficacy of ceftriaxone in neuroprotection of dopaminergic neurons in a rat model of Parkinson's disease was documented. However, which characteristics of ceftriaxone mediate its therapeutic effects remains unclear. Since at molecular level, neuronal ?-synuclein inclusions, and pathological ?-synuclein transmission play a leading role in initiation of Parkinson-like neurodegeneration, we thought of investigating, by circular dichroism spectroscopy, the capability of ceftriaxone to interact with ?-synuclein. We found that ceftriaxone binds with good affinity to ?-synuclein, and blocks its in vitro polymerisation. Considering this finding, we also documented that ceftriaxone exerts neuroprotective action in an in vitro model of Parkinson's disease. Our data, in addition to the findings on neuroprotective activity of ceftriaxone on Parkinson-like neurodegeneration in vivo, indicates ceftriaxone as a potential agent in treatment of Parkinson's disease.
PMID: 24099687 [PubMed - as supplied by publisher]